FTC Orders Hikma To Shed Drugs For $112M Baxter Deal
The Federal Trade Commission on Wednesday ordered Hikma Pharmaceuticals PLC to sell off an anti-seizure drug and an allergy and nausea treatment in order to go through with its $111.5 million...To view the full article, register now.
Already a subscriber? Click here to view full article